Phillip G. Febbo's most recent trade in Veracyte Inc was a trade of 2,955 Common Stock done at an average price of $26.7 . Disclosure was reported to the exchange on June 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Veracyte Inc | Phillip G. Febbo | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 02 Jun 2025 | 2,955 | 103,745 (0%) | 0% | 26.7 | 79,017 | Common Stock |
| Veracyte Inc | Phillip G. Febbo | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 24,160 | 106,700 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Phillip G. Febbo | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 32.87 per share. | 04 Mar 2025 | 4,467 | 86,110 (0%) | 0% | 32.9 | 146,808 | Common Stock |
| Veracyte Inc | Phillip G. Febbo | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 33.95 per share. | 04 Mar 2025 | 3,570 | 82,540 (0%) | 0% | 34.0 | 121,205 | Common Stock |
| Veracyte Inc | Phillip G. Febbo | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 30,589 | 113,003 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Phillip G. Febbo | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.84 per share. | 27 Feb 2025 | 15,672 | 97,331 (0%) | 0% | 33.8 | 530,340 | Common Stock |
| Veracyte Inc | Phillip G. Febbo | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.76 per share. | 27 Feb 2025 | 6,754 | 90,577 (0%) | 0% | 34.8 | 234,769 | Common Stock |
| Veracyte Inc | Phillip G. Febbo | Chief Scientific & Med Officer | Sale of securities on an exchange or to another person at price $ 44.09 per share. | 04 Dec 2024 | 3,934 | 82,414 (0%) | 0% | 44.1 | 173,447 | Common Stock |
| Veracyte Inc | Phillip G. Febbo | Chief Scientific & Med Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.12 per share. | 02 Dec 2024 | 6,738 | 86,348 (0%) | 0% | 44.1 | 297,281 | Common Stock |
| Veracyte Inc | Phillip G. Febbo | Chief Scientific & Med Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 39,904 | 93,086 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 7,556 | 14,786 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 4,534 | 4,534 | - | - | Performance Shares | |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 3,023 | 3,023 | - | - | Performance Shares | |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 3,522 | 8,475 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 3,522 | 0 | - | - | Performance Shares | |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 202.84 per share. | 21 Feb 2023 | 1,245 | 7,230 (0%) | 0% | 202.8 | 252,536 | Common Stock |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 217.19 per share. | 05 Nov 2022 | 821 | 4,953 (0%) | 0% | 217.2 | 178,313 | Common Stock |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 360.01 per share. | 05 Apr 2022 | 1,988 | 5,774 (0%) | 0% | 360.0 | 715,700 | Common Stock |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 363.84 per share. | 05 Apr 2022 | 131 | 7,762 (0%) | 0% | 363.8 | 47,663 | Common Stock |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 9,085 | 9,085 | - | - | Performance Shares | |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 3,029 | 7,893 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 2,851 | 0 | - | - | Performance Shares | |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 2,851 | 5,866 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 319.86 per share. | 22 Feb 2022 | 1,002 | 4,864 (0%) | 0% | 319.9 | 320,500 | Common Stock |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 406.83 per share. | 05 Nov 2021 | 1,000 | 3,015 (0%) | 0% | 406.8 | 406,830 | Common Stock |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 408.14 per share. | 05 Nov 2021 | 446 | 4,015 (0%) | 0% | 408.1 | 182,030 | Common Stock |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 447.65 per share. | 11 Jun 2021 | 400 | 4,751 (0%) | 0% | 447.7 | 179,060 | Common Stock |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 446.17 per share. | 11 Jun 2021 | 310 | 5,151 (0%) | 0% | 446.2 | 138,313 | Common Stock |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 449.02 per share. | 11 Jun 2021 | 290 | 4,461 (0%) | 0% | 449.0 | 130,216 | Common Stock |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 384.54 per share. | 05 Apr 2021 | 131 | 5,461 (0%) | 0% | 384.5 | 50,375 | Common Stock |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2021 | 3,173 | 0 | - | - | Performance Shares | |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2021 | 3,173 | 7,046 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 494.24 per share. | 17 Feb 2021 | 1,454 | 5,592 (0%) | 0% | 494.2 | 718,625 | Common Stock |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 350 | 3,873 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2021 | 4,140 | 4,140 | - | - | Performance Shares | |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2021 | 1,380 | 3,523 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 311.72 per share. | 05 Nov 2020 | 192 | 2,298 (0%) | 0% | 311.7 | 59,850 | Common Stock |
| Illumina Inc | Phillip G. Febbo | SVP Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 310.10 per share. | 05 Nov 2020 | 155 | 2,143 (0%) | 0% | 310.1 | 48,066 | Common Stock |